Their biological effects on LSCs were at least partly mediated by Notch4. Conversely, a pan-RAR antagonist delayed leukemogenesis and reduced stemness of EVI1high AML, suggesting potential novel treatment options for this aggressive AML subtype. The gene discussed is NOTCH4; the disease is acute myeloid leukemia.